The dysregulation of APP processing is implicated in neurodegenerative diseases, primarily Alzheimer's disease. Mutations in the APP gene can lead to increased production of beta-amyloid, accelerating plaque formation. Therapeutic interventions targeting APP processing enzymes, such as beta-secretase and gamma-secretase, are being investigated to reduce beta-amyloid production and ameliorate disease symptoms.
